The freedom to choose is integral to our daily lives, directs our interactions with patients, and is a key component of our conduct of human-subjects research. Most of the historical errors and atrocities in human experimentation had at their core a failure of consent. In response to those events, national and international law developed to direct researchers to a process of informed consent to participate in research. The application of this process, though, can be challenging. What does this process look like? Does it require written documentation, and if so what type? Who can give informed consent? Though researchers worldwide would agree on the concept of informed consent, the nuts and bolts of applying this ideal can create obstacles to researchers, confusion to subjects, and increasing regulations that may or may not help achieve the goal. I will review the current regulatory guidelines, summarize the types of consent, and consider options for improving the informed-consent process. Key words: informed consent, waiver of consent, surrogate decision maker. [Respir Care 2008;53(10):1337–1341. © 2008 Daedalus Enterprises]
have shaped federal and state law regarding research conduct. For researchers conducting studies in the United States, most research is governed by the United States Code of Federal Regulations Title 45, Part 46, known as the Common Rule. Drug studies are governed by the Food and Drug Administration’s regulations in Code of Federal Regulations Title 21, Part 50. Additional influences on the conduct of studies and the application of informed consent include state law, institutional policies, and in some situations, the study sponsor. I will discuss common themes, but the specifics depend on each institution’s interpretation of the regulatory guidelines.

Elements of Consent

The Common Rule specifies many criteria for informed consent. Table 1 shows the primary elements of the consent form. However, consent is about much more than just the form. Despite the large amount of time spent developing and fine-tuning the form, in reality consent is about a process that includes a non-coercive interaction between subject and investigator.

Types of Consent

Many types of consent are possible for clinical purposes that may or may not be acceptable for research studies. Types of consent include written, verbal, telephone, and faxed. In most institutions, verbal consent, such as may be sought for certain clinical procedures, is not allowed for research. As an example, calling a subject or legally authorized representative, discussing the study, and then having him/her consent over the telephone with another “witness” on the telephone call, may be acceptable in clinical emergencies but rarely if ever for research. On the other hand, that conversation could occur over the telephone and the subject (or legally authorized representative) could then sign a consent form and fax it to the researcher. The difference is that the subject has time to review the entire form, and the fax provides printed documentation of the consent. Regulations have not yet caught up with modern technology to provide consistent guidance regarding electronic signatures, e-mail consent, or video conferencing.

Depending on the study, the risk profile, and the circumstances surrounding consent, an institutional review board (IRB) may grant a waiver of documentation of consent or a waiver of consent itself. Both are relatively uncommon. The latter is more common in situations such as screening medical records for inclusion criteria for a study or retrospective review of records for epidemiology purposes. A distinct category of research that sometimes qualifies for waiver of consent is emergency research. Studies that might qualify for this accommodation include those where immediate intervention is required to obtain benefit (e.g., studies on pre-hospital treatment of myocardial infarction, stroke, or resuscitation). The criteria for waived consent include: no more than minimal risk, or the risk from the condition/illness is high; the intervention will not adversely affect the subject’s rights; the research is not practical without the waiver; and information will be provided to and consent obtained from the subjects at a later date, if feasible. For emergency research, community notification might be required. Emergency research conducted under waiver of consent is closely monitored by regulatory authorities to ensure the welfare of subjects who, by design, and as a consequence of their illness or injury, do not have the option to say yes or no.

Who Can Provide Consent?

Ideally, informed consent is always provided by the subject, under optimal conditions, without any sense of time or other pressure. This is not always possible, though, and in many cases the consent process is impacted by the illness or injury that makes the patient eligible for the study. When the subject is not competent to consent, investigators look to a surrogate for consent. Note that “competent to consent” may be more rigorously interpreted for mental competency than defined for research. A subject who has been deemed legally incompetent cannot consent to participate in research; a guardian may have been assigned, and the guardian could stand in for the subject for research consent. In most medical situations, though, the issue of competence is decided clinically based on the extent of injury, illness, pain, sedation, et cetera, and how those might affect the subject’s ability to understand and freely consent. This assessment is often left to the clinical discretion of the investigator, although some regulatory
Obtaining Consent

Presentation of a study to a subject or legally authorized representative is about much more than just getting a signature on the consent form. Though regulations are more specific about the elements included in a consent form, the consent process is in fact probably more important than the form itself. This process starts with the approach to the subject or legally authorized representative. Ideally the topic of research can be introduced by someone known to the subject, so the subject has the ability to say no without having to directly refuse the research team. Similarly, if the research involves a telephone survey, the research should be “announced” first in the form of a letter or flyer so the subject doesn’t suffer the “telemarketing” experience of a cold call from an unknown entity. When possible, it’s best if the person who contacts the subject in the consent process is separate from the clinical team, so that there is no risk of the subject feeling coerced because of concern that his or her clinical care depends on study participation.

Once the consent process is underway, it is best conducted in a quiet location and under conditions that allow time for the subject or legally authorized representative to consider the pros and cons and review the materials. Some research, though, such as research in emergency and critical-care situations, makes that difficult, given the abrupt onset of illness/injury and the short period of time available in which care/interventions could be useful. These situations require even more sensitivity on the part of researchers, to minimize the risk of coercion or adding stress on the subject or legally authorized representative. Additionally, often the clinician conducting the consent process is involved in the research because they hope the intervention will work. It’s very important to maintain balance in the presentation of risks and benefits and avoid therapeutic misconception—the perception by the subject that being in the study will improve the outcome. If that were known, there would be no study and the intervention would simply be offered. Though the research may benefit society in the long run, in all cases the benefits are at best possible and certainly unknown at the level of the individual.

Different institutions, depending on location, referral pattern, and population, may have additional challenges to incorporate into the consent process. For instance, a high illiteracy rate in the study region may require a special approach to consent. Enrolling only subjects who can read and write would unfairly limit access to research and violate the tenet of justice. The investigator would need to work with the local IRB(s) to devise a consent process that incorporates the required elements of consent but also responds to the unique issues of the study’s subjects. A possible solution could be a subject advocate who is present during consent and could attest to comprehension and consent, rather than using a written document, which would be meaningless if the subject were illiterate.

Another factor that requires sensitivity is cultural differences. A study in The Archives of Internal Medicine in 2002 documented an increased distrust of whites among African-Americans with regard to research.4 African-Americans were more likely to think they might be used as “guinea pigs,” that the investigator wouldn’t explain things fully, or that the investigator was giving medications just to experiment on them. Clearly we have a long way to go to repair the effects of past research tragedies.

Consent Examples

- “I’m just going to look at the medical records of patients with chronic obstructive pulmonary disease to report our experience with bi-level positive airway pressure.”

IRB approval is required because the investigator will be accessing medical records. However, it is likely that there will be a waiver of consent, because it is a retrospective chart review, there is no intervention, the risk to subjects is minimal (privacy and confidentiality concerns only), and there is no practical way to do the study otherwise.

- “I described the study, but I’m not sure the husband really understood. He just signed the form.”

Remember that the consent process means trying to ensure the subject or legally authorized representative understands what’s being asked. One strategy is to ask the
subject or legally authorized representative a couple questions about the study: “What disease are we studying?” “What’s one risk of the study?” Most importantly, ensure that the person is aware that participation is voluntary and won’t otherwise affect the care. Particularly in emergency or intensive-care research, families are overwrought and grasp for any possible benefit. It’s our job to make sure they have the best opportunity to freely accept or decline enrollment.

- “I talked with the family and they seemed interested, but then they just left after being here all night. Should I call them back in?”

Be sensitive to the family’s needs. If permitted by the IRB, it may be an option to call them at home and fax them a copy of the consent, which they could sign and fax to you. When calling a family at home, always be sure to mention up front that the call is not about a problem with their loved one (those are the calls they fear when they go home), but just about a research study. If the investigator hasn’t talked with the family yet, do not call them directly. Ask a member of the clinical team to call and introduce the researcher.

- “The niece is here and willing to sign the consent form. Is that OK?”

The answer depends on the state and local regulations that define the list of legally authorized representatives. In many states, nieces, aunts, cousins, et cetera are not on that list.

**Quality of Informed Consent**

Despite our best efforts, many subjects or legally authorized representatives may not be fully “informed” when providing consent for research. In addition, was it an added burden or did they feel like it helped them contribute? Several studies, which involved both adults and children, have looked at these issues. A survey of Phase I-III cancer clinical trials used the Quality of Informed Consent tool.5 In a survey of 207 (72%) of the patients, 92% were satisfied with the consent process, 74% did not realize the treatment was non-standard, 63% didn’t realize there was a potential for risk, and only 26% realized that trials mainly benefit the future. Interestingly, only 46% of the providers realized the latter.

Another study evaluated understanding of the concept of randomization. The researchers recorded 137 consent conferences in childhood leukemia studies.6 In 83% of the recordings, randomization was discussed, but after the conference only half of the parents understood the concept. Discussion of trial details and the presence of a nurse acting as subject advocate during the consent conference were associated with better understanding.

**Improving Informed Consent**

Given the above examples of less-than-thorough understanding of what has been consented to, how can this process be improved for subjects? One way may be to simplify the consent form by removing information and risk language that’s not specific to the research study itself. Using topic sentences as headings may help get across key concepts, if such a format is allowed by the IRB. Though not yet widely required, asking the subject a question or two at the end of the consent process may help to assess understanding. A review of 42 trials that studied consent methods found that multimedia approaches and enhanced consent forms had little effect.5 In other words, expansive brochures or writing more in the consent form did not help subjects understand what they were being told or asked. However, certain other strategies, such as providing additional time by a study member or including a neutral educator, made more of a difference in the subject’s understanding. This highlights the simple fact that, though there is a lot of effort spent on the consent form, the process and the communication between human beings plays a large role in a subject’s understanding. More research is needed. For example, how do different locations of consent (bedside vs private room vs busy area) affect comprehension? Also, how does the severity of illness/injury impact understanding? Do subjects who were enrolled by a legally authorized representative ultimately concur with that decision? We need to be able to tailor the consent process to the person being asked for consent and to begin to apply learning theory and communication tools used in education to improve our consent process. Though the consent form is important, the consent process is key.

**Summary**

The ability to accept or decline access to private information is a core right that we hold dear. This extends to consent for clinical research. There are federal, state, and institutional regulations that dictate this process, including what must be included in the consent form and who can consent. However, the process of informed consent is less regulated and there are few, if any, requirements that there be an assessment of whether the process is actually working to provide a truly informed consent. More research is needed to identify the types of processes that can help with this comprehension. In the meantime, providing adequate time and, when possible, having a neutral person involved with the consent conference may help comprehension. Most importantly, remember that research is a privilege, not a right, and the goal isn’t just to get the person to sign the consent form but, rather, to present the study in a clear way and then let the subject decide. That will truly lead to
a partnership that will help further research while maintaining the integrity of the process.

REFERENCES